Les Charges D'Exploitation Changement Date
Acadia Pharmaceuticals USD 270.57M 450K 2026-09
Agios Pharmaceuticals USD 155.3M 24.53M 2026-06
Akebia Therapeutics USD 63.08M 8.26M 2025-12
ALKERMES USD 1.86B 56.17M 2026-09
Alnylam Pharmaceuticals USD 1.11B 52.78M 2026-09
Amgen USD 5.69B 6B 2026-09
Biogen USD 2.32B 663.6M 2026-09
BioMarin Pharmaceutical USD 819.04M 5.5B 2026-09
Exelixis USD 390.27M 10M 2026-09
Immunic USD 23.33M 2.67M 2025-12
Incyte USD 5.64B 4.67B 2026-09
Ionis Pharmaceuticals USD 373M 2.76M 2026-09
MacroGenics USD 25.15M 17.72M 2026-09
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Neurocrine Biosciences USD 779.7M 40.6M 2026-09
Prothena USD 19.7M 5.6M 2026-06
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Ultragenyx Pharmaceutical USD 283M 6M 2026-09
Vertex Pharmaceuticals USD 2.18B 118.2M 2026-09